VOA慢速英语2021 大批欧洲国家暂停使用阿斯利康疫苗 欧洲药管局仍称其安全（在线收听）

A European Union health official said Tuesday there was “no indication” that the AstraZeneca coronavirus vaccine caused blood clots in some people.

欧盟官员周二表示，没有迹象表明阿斯利康新冠疫苗在某些人当中引发了血栓。

Emer Cooke, the head of the European Medicines Agency (EMA), spoke to reporters Tuesday. She said there was “no indication that vaccination has caused these conditions.” The EMA director added, “While the investigation is ongoing, we are currently still firmly convinced that the benefits of the AstraZeneca vaccine in preventing Covid-19, with its associated risk of hospitalization, outweigh the risk of the side effects.”

欧洲药品管理局负责人埃默·库克周二对记者发表了讲话。她说，没有迹象表明是疫苗引发了这些症状。这位负责人还表示，“虽然调查在进行中，但是我们目前仍然坚定地相信，阿斯利康疫苗在防范新冠肺炎及相关住院风险方面的益处超过了副作用的风险。”

The statement came after Sweden and Latvia became the latest European countries to suspend use of the AstraZeneca vaccine. Anders Tegnell of the Swedish Public Health Agency said earlier on Tuesday, ”The decision is a precautionary measure.” He added Sweden would wait for the results of the European Medicines Agency’s study.

这份声明是在瑞典和拉脱维亚成为最新一批暂停使用阿斯利康疫苗的欧洲国家之后发表的。瑞典公共卫生局的安德斯·特涅尔周二早些时候表示：“该决定是一项预防措施。”他还表示，瑞典将会等待欧洲药品管理局的研究结果。

Denmark, Iceland, and Norway were the first countries to temporarily stop using the vaccine. Ireland announced a similar decision over the weekend. On Monday, France, Germany, Spain and Italy were among the countries that suspended use of the vaccine.

丹麦、冰岛和挪威是首批暂停使用该疫苗的国家。爱尔兰在周末宣布了一项类似的决定。周一，法国、德国和意大利也加入了暂停使用这种疫苗的国家行列。

Their decision came after reports of bleeding and blood clots among those who received the vaccine made by AstraZeneca with the University of Oxford.

有报道称阿斯利康公司联合牛津大学生产的这种疫苗的接种者出现了出血和血栓的症状，之后这些国家做出了决定。

AstraZeneca had said earlier that there is no evidence its vaccine carries an increased risk of blood clots. By March 8, there have been 37 reports of blood clots among the more than 17 million people who have received the vaccine across the EU and Britain, the company said.

阿斯利康公司此前曾表示，没有证据表明该公司的疫苗会增加血栓的风险。该公司表示，截至3月8日，在欧盟和英国范围内已经接种疫苗的1700多万人中，报告有37例出现血栓。

Ann Taylor is AstraZeneca’s Chief Medical Officer. She added: “the number of cases of blood clots reported in this group is lower than the hundreds of cases that would be expected among the general population.”

安·泰勒是阿斯利康公司的首席医疗官。她补充道：“该组报告的血栓病例数低于一般人群中预期会出现的数百例的病例数。”

Both the World Health Organization (WHO) and the European Medicines Agency (EMA) said they are studying the cases.

世卫组织和欧洲药品管理局都表示正在研究这些病例。

The AstraZeneca vaccine is one of three vaccines approved for emergency use in Europe. The other two are made by the companies Pfizer-BioNTech and Moderna.

阿斯利康疫苗是欧洲批准用于紧急用途的3种疫苗之一。另外两种是由辉瑞-生物新科技公司以及莫德纳公司生产的。

In the United States, health officials have approved vaccines from Pfizer-BioNTech, Moderna and Johnson & Johnson for emergency use. AstraZeneca is planning to seek U.S. government approval in the coming months.

美国卫生官员已经批准了辉瑞-生物新科技、莫德纳以及强生公司的疫苗用于紧急用途。阿斯利康公司计划在未来几个月内寻求美国政府的批准。

Vaccine for the world

全球疫苗

When the AstraZeneca vaccine was approved for emergency use in Britain last December, the shot was described as the “vaccine for the world.” The vaccine costs much less than those from Pfizer and Moderna. It also does not require extreme cold storage making it easier to use in countries with limited resources.

去年12月当阿斯利康疫苗在英国获准用于紧急用途时，该疫苗被称为世界疫苗。这种疫苗的价格远低于辉瑞和莫德纳公司的疫苗。它还不需要极低温冷藏，因此更便于在资源有限的国家使用。

COVAX is an international program to deploy coronavirus vaccines to poor people around the world. Last month, the program sent its first supply of 600,000 shots made by AstraZeneca to the African country of Ghana. Others have gone to Nigeria, Kenya and the Asian countries of the Philippines and Indonesia. The program hopes to provide at least 2 billion shots, mainly from AstraZeneca, especially to poor countries around the world.

新冠肺炎疫苗实施计划是一项旨在向世界各地贫困人口提供新冠病毒疫苗的国际项目。上个月，该项目给非洲国家加纳送去了第一批由阿斯利康公司生产的60万剂疫苗。其它疫苗则被送到了尼日利亚、肯尼亚以及亚洲的菲律宾和印尼。该项目希望至少提供20亿剂主要来自于阿斯利康公司的疫苗，尤其是面向世界各地的贫穷国家。

The largest user of AstraZeneca’s vaccine, however, is India. The country is home to the Serum Institute of India where most of the AstraZeneca vaccine is manufactured.

然而阿斯利康疫苗的最大用户是印度。该国是印度血清研究所的所在地，其中大部分阿斯利康疫苗都在此生产。

Health officials reported that over 23.4 million people have received the AstraZeneca shot in India. That is out of 25.6 million people who have been vaccinated in that country. Health officials told the Press Trust of India news agency on Saturday that 234 cases of adverse events had been reported after receiving any vaccine. That number includes 71 deaths. However, they said there is no link to the vaccine. The government is now studying the cases for a final study.

卫生官员报告称，印度已经有超过2340万人接种了阿斯利康疫苗。这包含在该国已经接种的2560万人当中。卫生官员周六对印度新闻信托社表示，印度在接种疫苗后已经报告了234例不良反应事件。其中包括71例死亡。但是他们称与疫苗没有联系。印度政府现在正在研究这些案例，以作为最后一项研究。

In Thailand, Prime Minister Prayuth Chan-ocha received his first of the two-shot AstraZeneca vaccine. He said, “There are people who have concerns. But we must believe doctors, believe in our medical professionals.”

泰国总理巴育接种了他的第一针阿斯利康疫苗。他说：“有些人担心，但是我们必须相信医生，相信我们的医疗专家。”